BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Wedding trip Objections in Europe - 2How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- 3American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- 4RFK Jr. guts the US childhood vaccine schedule despite its decades-long safety record
- 5Manual for Individual accounting Rudiments for Fledglings
- Virtual reality opens doors for older people to build closer connections in real life
- New law puts familiar drinks, creams and gummies in legal limbo
- Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- 6 Well known Nissan Vehicles in the U.S.
- Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Lego's $650 Pokémon set is already sold out as demand, preorders surge
